Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis

Journal of Thoracic Oncology

Volumn 11, Issue 12, 2016, Pages 2048-2050

  Reungwetwattana, Thanyanan ^a   Adjei, Alex A ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; GAMMA INTERFERON; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TEMOZOLOMIDE;

ADJUVANT THERAPY; BACTERIAL GROWTH; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DRUG APPROVAL; DRUG WITHDRAWAL; EDITORIAL; FASCIITIS; FEVER; GLIOBLASTOMA; HERPES SIMPLEX; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; LICHENOID ERUPTION; LUNG CANCER; LUNG INFECTION; LUNG TUBERCULOSIS; LYMPHOCYTOPENIA; MELANOMA; MYASTHENIA GRAVIS; MYCOBACTERIUM TUBERCULOSIS; MYOCARDITIS; NON SMALL CELL LUNG CANCER; NONHUMAN; PNEUMOCYSTOSIS; PNEUMONIA; PROTEIN EXPRESSION; RETINA VASCULITIS; RHABDOMYOLYSIS; SARCOIDOSIS; SEPSIS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THRUSH; TREATMENT WITHDRAWAL; TUMOR MICROENVIRONMENT; UPREGULATION; URINARY TRACT INFECTION; WEIGHT REDUCTION; ATYPICAL MYCOBACTERIOSIS; IMMUNOLOGY; LUNG TUMOR;

HUMANS; LUNG NEOPLASMS; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; TUBERCULOSIS, PULMONARY;

EID: 85010775162     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.10.008     Document Type: Editorial

References (20)

1. Mellman I, Coukos G, Dranoff G Cancer immunotherapy comes of age Nature 2011,480,480-489
2. Schreiber RD, Old LJ, Smyth MJ Cancer immunoediting integrating immunity's roles in cancer suppression, promotion Science 2011,331,1565-1570
3. Borghaei H, Paz-Ares L, Horn L, et al Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 2015,373,1627-1639
4. Brahmer J, Reckamp KL, Baas P, et al Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 2015,373,123-135
5. Herbst RS, Baas P, Kim DW, et al Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) a randomised controlled trial Lancet 2016,387,1540-1550
6. Hodi FS, O'Day SJ, McDermott DF, et al Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 2010,363,711-723
7. Cousin S, Italiano A Molecular pathways immune checkpoint antibodies, their toxicities Clin Cancer Res 2016,22,4550-4555
8. Robert C, Long GV, Brady B, et al Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 2015,372,320-330
9. Rizvi NA, Mazieres J, Planchard D, et al Activity, safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063) a phase 2, single-arm trial Lancet Oncol 2015,16,257-265
10. Rosenberg JE, Hoffman-Censits J, Powles T, et al Atezolizumab in patients with locally advanced, metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy a single-arm, multicentre, phase 2 trial Lancet 2016,387,1909-1920
11. Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA Opportunistic infections in patients treated with immunotherapy for cancer J Immunother Cancer 2014,2,19
12. Lee JJ, Chan A, Tang T Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma Acta Oncol 2016,55,519-520
13. Fujita K, Terashima T, Mio T Anti-PD1 Antibody treatment, the development of acute pulmonary tuberculosis J Thorac Oncol 2016,11,2238-2240
14. Kaufmann SH How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001,1,20-30
15. Tascon RE, Stavropoulos E, Lukacs KV, Colston MJ Protection against Mycobacterium tuberculosis infection by CD8\+ T cells requires the production of gamma interferon Infect Immun 1998,66,830-834
16. Jurado JO, Alvarez IB, Pasquinelli V, et al Programmed death (PD)-1PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis J Immunol 2008,181,116-125
17. Lazar-Molnar E, Chen B, Sweeney KA, et al Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis Proc Natl Acad Sci USA 2010,107,13402-13407
18. Lapadula G, Soria A, Bandera A, et al Unmasking tuberculosis in the era of antiretroviral treatment Eur Respir J 2012,39,1064-1075
19. Yovino S, Grossman SA Severity, etiology, possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas CNS Oncol 2012,1,149-154
20. de Paiva TF Jr, de Barrose Silva MJ, Rinck JA Jr, Fanelli MF, Gimenes DL Tuberculosis in a patient on temozolomide a case report J Neurooncol 2009,92,33-35